604 related articles for article (PubMed ID: 25844756)
1. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
McIntyre RS; Cucchiaro J; Pikalov A; Kroger H; Loebel A
J Clin Psychiatry; 2015 Apr; 76(4):398-405. PubMed ID: 25844756
[TBL] [Abstract][Full Text] [Related]
2. Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features:
Singh MK; Pikalov A; Siu C; Tocco M; Loebel A
J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):590-598. PubMed ID: 32392455
[No Abstract] [Full Text] [Related]
3. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis.
Swann AC; Fava M; Tsai J; Mao Y; Pikalov A; Loebel A
CNS Spectr; 2017 Apr; 22(2):228-235. PubMed ID: 28300012
[TBL] [Abstract][Full Text] [Related]
4. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Loebel A; Cucchiaro J; Silva R; Kroger H; Hsu J; Sarma K; Sachs G
Am J Psychiatry; 2014 Feb; 171(2):160-8. PubMed ID: 24170180
[TBL] [Abstract][Full Text] [Related]
5. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study.
Suppes T; Silva R; Cucchiaro J; Mao Y; Targum S; Streicher C; Pikalov A; Loebel A
Am J Psychiatry; 2016 Apr; 173(4):400-7. PubMed ID: 26552942
[TBL] [Abstract][Full Text] [Related]
6. Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension.
Goldberg JF; Ng-Mak D; Siu C; Chuang CC; Rajagopalan K; Loebel A
CNS Spectr; 2017 Apr; 22(2):220-227. PubMed ID: 28264739
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
8. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Loebel A; Cucchiaro J; Silva R; Kroger H; Sarma K; Xu J; Calabrese JR
Am J Psychiatry; 2014 Feb; 171(2):169-77. PubMed ID: 24170221
[TBL] [Abstract][Full Text] [Related]
9. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.
Tsai J; Thase ME; Mao Y; Ng-Mak D; Pikalov A; Loebel A
CNS Spectr; 2017 Apr; 22(2):236-245. PubMed ID: 28357969
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.
Sajatovic M; Forester BP; Tsai J; Kroger H; Pikalov A; Cucchiaro J; Loebel A
J Clin Psychiatry; 2016 Oct; 77(10):e1324-e1331. PubMed ID: 27529375
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.
van der Loos ML; Mulder PG; Hartong EG; Blom MB; Vergouwen AC; de Keyzer HJ; Notten PJ; Luteijn ML; Timmermans MA; Vieta E; Nolen WA;
J Clin Psychiatry; 2009 Feb; 70(2):223-31. PubMed ID: 19200421
[TBL] [Abstract][Full Text] [Related]
13. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
Findling RL; Nyilas M; Forbes RA; McQuade RD; Jin N; Iwamoto T; Ivanova S; Carson WH; Chang K
J Clin Psychiatry; 2009 Oct; 70(10):1441-51. PubMed ID: 19906348
[TBL] [Abstract][Full Text] [Related]
14. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
15. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
18. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
19. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.
Amsterdam JD; Wang CH; Shwarz M; Shults J
J Affect Disord; 2009 Jan; 112(1-3):219-30. PubMed ID: 18486235
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
